AzTrials
AzTrials

Breast CancerPhase 2NCT07197697

A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

A Phase 2 study testing Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy in people with Breast Cancer, run by Anhui Provincial Cancer Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a prospective, multicenter, single-arm, exploratory study. 30 patients with locally advanced HR+/HER2- breast cancer who have not received any treatment were recruited to receive apalutamide voraparib combined with chemotherapy for neoadjuvant therapy. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Breast Cancer
What is being tested?
Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
No sites listed yet
Study dates
10 Oct 2025to 1 Nov 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The patient must meet all of the following criteria to be included in the study:
  • Age ≥ 18 years and ≤ 75 years, regardless of gender;
  • The primary lesion tissue pathology is confirmed as HR+/HER2- breast cancer, following the 2018 ASCO/CAP breast cancer HER2 testing guidelines and the 2010 ASCO/CAP breast cancer ER/PR testing guidelines for interpretation. HER2-negative is defined as confirmed by the pathology laboratory with an immunohistochemistry (IHC) score of HER2 0/1+ or 2+ and negative in in situ hybridization (ISH), and estrogen receptor positive (ER+) breast cancer with or without progesterone receptor (PgR) expression;
  • Tumor histological grade 3, or histological grade 2 with the percentage of ER expression level between 1-10%;
  • According to the American Joint Committee on Cancer (AJCC) 8th edition TNM classification, the clinical stage should be T1c-T2cN1-2 or T3-4cN0-2, M0 stage;
  • At least one measurable lesion (in accordance with the RECIST 1.1 version standard);
Show all 15Show fewer
  • Expected survival time ≥ 12 weeks;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
  • The subject has no severe blood, heart, lung, liver, or kidney function abnormalities and immunodeficiency diseases. The functional level of important organs within one week before the first administration must meet the following requirements:
  • Blood routine: HGB ≥ 90g/L; WBC ≥ 4.0×109/L; NEUT ≥ 2.0×109/L; PLT ≥ 100×109/L;
  • Blood biochemistry: TBIL ≤ 1.5×ULN; ALT and AST ≤ 3×ULN (for those with liver metastasis, ALT and AST ≤ 5×ULN); BUN and Cr ≤ 1.5×ULN and creatinine clearance rate ≥ 50 mL/min;
  • Cardiac color Doppler ultrasound before the first administration must meet: left ventricular ejection fraction (LVEF) > 50%;
  • Thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); if abnormal, T3 and T4 levels should be examined; if T3 and T4 levels are normal, the subject can be included;
  • Pregnant patients should have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures during the test period;
  • The subject voluntarily joins this study, signs the informed consent, has good compliance and is willing to cooperate with follow-up.

Who cannot join

  • If the patient meets any of the following conditions, they will not be eligible:
  • Patients with stage IV metastatic breast cancer or other conditions deemed by the researchers as not achievable through neoadjuvant therapy for radical surgical resection;
  • Bilateral invasive breast cancer;
  • Breast cancer patients who have previously received anti-tumor treatments such as chemotherapy, endocrine therapy, or undergone breast surgery (except for the diagnostic biopsy of primary breast cancer);
  • Patients who participated in other drug clinical trials within 4 weeks prior to enrollment, received major surgical treatment, incisional biopsy, or significant traumatic injury (except for the diagnostic biopsy of primary breast cancer);
  • Within 4 weeks before the first administration or planned to receive attenuated live vaccines during the study;
Show all 22Show fewer
  • Patients with other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or papillary thyroid carcinoma;
  • Patients receiving any other anti-tumor treatment simultaneously;
  • Patients with a known history of allergy to the components of this study drug;
  • Patients with a clear history of neurological or mental disorders, including epilepsy or dementia, or a history of substance abuse or drug use for mental disorders;
  • Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
  • Pregnant or lactating female patients, or female patients with reproductive capacity and positive baseline pregnancy test results;
  • Patients with active infectious diseases;
  • Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy;
  • Patients with active or potentially recurrent autoimmune diseases, except for: vitiligo, alopecia, psoriasis or eczema that do not require systemic treatment; hypothyroidism caused by autoimmune thyroiditis, requiring only a stable dose of hormone replacement therapy; type 1 diabetes requiring only a stable dose of insulin replacement therapy;
  • According to the investigator's judgment, there are serious diseases that endanger the patient's safety or affect the patient's ability to complete the study (including but not limited to drug-controlled interstitial lung disease, severe pulmonary dysfunction/disease, cerebrovascular accident, severe diabetes);
  • Excluded patients with any of the following cardiovascular diseases:
  • Within 6 months before the first administration, experienced myocardial infarction, unstable angina pectoris, pulmonary embolism, acute/ persistent myocardial ischemia, cerebrovascular accident, transient cerebral ischemic attack, or other clinically significant/ requiring drug treatment intervention thromboembolic or ischemic events;
  • Had NYHA III-IV grade congestive heart failure in the past and/or currently;
  • Had severe arrhythmias that require drug treatment in the past and/or currently;
  • Within 12-lead ECG before the first administration showed a mean QT interval (QTcF) > 470 ms.
  • The investigator determines that the patient is not suitable to participate in this study.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Pan Yueyin contact

13805695539

panyueyin@ustc.edu.cn

About this study

This study is a prospective, multicenter, single-arm, exploratory study. 30 patients with locally advanced HR+/HER2- breast cancer who have not received any treatment were recruited to receive apalutamide voraparib combined with chemotherapy for neoadjuvant therapy. This study adopts Simon's two-stage design: in the first stage, 12 patients need to be enrolled. If among these 12 patients, 1 or fewer patients achieve tpCR, the study will be prematurely terminated due to early failure. Otherwise, 18 patients will be enrolled in the second stage. If 7 or more patients achieve tpCR among the 30 patients, the study achieves the expected results, and the drug can be further studied; otherwise, the study fails, and the drug does not need further study. The aim of this study is to evaluate the efficacy and safety of apalutamide voraparib combined with chemotherapy for neoadjuvant therapy in patients with HR+/HER2- breast cancer.

Conditions
Breast Cancer
Being tested
Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapyDrug

    The dosage of Iparomlimab and Tuvonralimab Injection is 5mg/kg, administered intravenously, with each treatment cycle lasting every 3 weeks. The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles. A total of 8 cycles of neoadjuvant chemotherapy combined with immunotherapy were performed before the surgery. It is recommended that the surgery be conducted within 4 weeks after the completion of neoadjuvant treatment. The postoperative adjuvant treatment can be continued with postoperative adjuvant chemotherapy and the treatment of the etolo combination antibody according to the decision of the researcher and/or the willingness of the subject.

Study groups in NCT07197697
Study groupRoleWhat they receive
treatment groupExperimentalIparomlimab and Tuvonralimab combined with chemotherapy
Receives: Drug: Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. tpCR rate，total physiological complex response

    After the resection of the primary tumor, microscopic examination of the breast and the ipsilateral axillary lymph nodes revealed no invasive tumor cells (ypT0/is ypN0)

    Measured: From the time of enrollment to one month after the surgery

Secondary outcomes (6)

  1. bpCR，breast physiological complex response

    After the primary tumor was removed, microscopic examination of the breast revealed no invasive tumor cells (ypT0/is)

    Measured: From the time of enrollment to one month after the surgery

  2. EFS，Event-free survival

    The time from the start of medication to the occurrence of any of the following events for the first time: disease progression making surgical treatment impossible, local or distant recurrence, death due to any cause, etc.

    Measured: baseline，1year，up to 2year

  3. ORR，Objective Response Rate

    The proportion of patients whose tumor volume has decreased by 30% and has remained stable for more than four weeks is referred to as the sum of complete response (CR) and partial response (PR).

    Measured: 6-12 months

  4. OS，Overall Survival

    Refers to the period from the start of medication use until death occurs due to any cause.

    Measured: baseline，1year，up to 2year

  5. adverse event

    Collect all adverse events that occurred in all subjects from the signing of the informed consent to 28 days after the cessation of medication, including clinical symptoms and abnormal vital signs, as well as abnormalities in laboratory tests. Record the clinical manifestations, severity, occurrence time, duration, treatment methods, prognosis, and determine the correlation between these events and the test drug.

    Measured: up to 2year

  6. PRO

    Outcome indicators reported by the patients，Score using the Chinese version of the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30, V3.0)

    Measured: through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2025
  2. Study start10 Oct 2025 (estimated)
  3. Primary completion1 Nov 2027 (estimated)
  4. Study completion1 Nov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07197697
Sponsor's protocol ID
2025-LLYJ-0007
Status last verified
Sep 2025
First submitted
2 Sep 2025
Last updated
29 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy in people with Breast Cancer, run by Anhui Provincial Cancer Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pan Yueyin (13805695539, panyueyin@ustc.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

tpCR rate，total physiological complex response (time frame: From the time of enrollment to one month after the surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07197697.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in